Compare BridgeBio Pharma Inc (BBIO) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Quest Diagnostics Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Quest Diagnostics Inc trades at $237.5 (market cap $26.21B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.45% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | DGX | |
|---|---|---|
Market Cap | $16.36B | $26.21B |
Sector | Health | Health |
52-Week High | $90.17 | $238.50 |
52-Week Low | $47.29 | $173.49 |
Enterprise Value | $18.14B | $31.97B |
Dividend Yield | — | 1.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
